Sun Pharma Acquires 3 Brands To Boost Its Portfolio

Sun Pharma has acquired 3 brands from a healthcare research entity ‘Aksigen Hospital Care’. The 3 acquired brands are – Disperzyme, Disperzyme-CD, and Phlogam.

Sun Pharma, a large pharmaceutical company, revealed on Monday that it has purchased three products from Aksigen Hospital Care: Disperzyme, Disperzyme-CD, and Phlogam.

Sun Pharma stated in a BSE stock filing that Aksigen is a Mumbai-based, research-driven healthcare organization with more than 20 years of experience in the industry.

The first Trypsin, Bromelain, and Rutoside enzyme-bioflavonoid combination is Disperzyme and Phlogam (“TBR”) “) in order to finish a clinical trial in India and receive DCGI approval. 

In 2013, Aksigen registered and introduced the brands in India, according to a news release from Sun Pharma.

“The inclusion of Disperzyme and Phlogam boosts our line of anti-inflammatory medications even more. 

This combination of systemic enzyme therapy is intended to reduce edema and hasten the healing process. 

In a comparative clinical trial conducted in India, the brands dramatically improved postoperative inflammation and pain control and resolution”, Kirti Ganorkar is the CEO of Sun Pharma’s Indian division.

In India, there is an about 500 crore rupee market for proteolytic enzymes used to treat edema, pain, and healing.

Also Read: Top 10 Pharma Companies In India

SEZABY, an injection of phenobarbital sodium for the management of newborn seizures, was introduced by Sun Pharmaceutical Industries last week in the US.

According to the manufacturer, SEZABY is the first and only medication authorized by the USFDA for the management of newborn seizures in term and preterm infants.

The USFDA designated Sun Pharma’s SEZABY as a “orphan medication” to treat newborn seizures.

The USFDA designates a treatment as an orphan drug if it is designed to treat an ailment that affects less than 2 lakh people in the US or won’t be commercially successful within seven years of approval.

At one o’clock on Monday afternoon, the value of a share of Sun Pharma had increased by 0.33 percent.